885692-52-4

Basic information

• Product Name: JNJ-28312141
• Synonyms: JNJ-28312141;JNJ-28312141(JNJ-141);4-Cyano-N-(5-(1-(2-(dimethylamino)acetyl)piperidin-4-yl)-2',3',4',5'-tetrahydro-[1,1'-biphenyl
• CAS NO: 885692-52-4
• Molecular Formula: C₂₆H₃₂N₆O₂
• Molecular Weight: 460.58
• Mol File: 885692-52-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.27±0.1 g/cm3(Predicted)
• PKA: 7.30±0.10(Predicted)
• CAS DataBase Reference: JNJ-28312141(CAS DataBase Reference)
• NIST Chemistry Reference: JNJ-28312141(885692-52-4)
• EPA Substance Registry System: JNJ-28312141(885692-52-4)

Safety Data

• Hazardous Substances Data: 885692-52-4(Hazardous Substances Data)

Usage

General Description

JNJ-28312141 is a selective and potent antagonist of the orexin-2 receptor (OX2R) and has been studied for its potential in treating sleep disorders such as insomnia and narcolepsy. It has been shown to reduce wakefulness and promote sleep in animals, making it a promising candidate for the development of medications to regulate sleep-wake cycles. Additionally, JNJ-28312141 has been investigated for its potential in treating addiction and other neurobehavioral disorders, as it affects the activity of the orexin system, which plays a role in regulating reward and motivation. Further research is needed to fully explore the potential therapeutic applications of this compound.

Upstream product

• 60853-81-8 N,N-dimethylaminoacetyl chloride hydrochloride 
• 1118-68-9 dimethylaminoacetic acid 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 885693-02-7 (4-{[4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carbon-yl]-amino}-3-cyclohex-1-enyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 885693-01-6 4-(4-amino-3-cyclohex-1-enyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 885693-00-5 4-(4-amino-3-bromophenyl)piperidine-1-carboxylic acid tert-butyl ester 
• 170011-57-1 tert-butyl 4-(4-aminophenyl)piperidin-1-carboxylate 
• 873454-43-4 4-(4-aminophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 108-24-7 acetic anhydride 

Relevant articles and documents

POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION

Positron emission tomography (PET) radiotracers for imaging macrophage colony stimulating factor-1 receptors in a subject afflicted with or suspected of being afflicted with a neuroinflammatory or neurodegenerative disease or disorder are disclosed.

METHOD OF INHIBITING C-KIT KINASE

A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I′: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.